SGLT-2抑制剂:1型糖尿病治疗的希望,还是梦想?  

SGLT-2i Therapy:Booming Prospect or Pipe Dream for Type 1 Diabetes?

作　　者：向琴 夏旋 XIANG Qin;XIA Xuan(Department of Physiology and Pathophysiology,College of Medical School,Three Gorges University,Yichang Hubei 443002,China)

机构地区：[1]三峡大学医学院生理与病理生理学系,湖北宜昌443002

出　　处：《药品评价》2019年第3期10-14,共5页Drug Evaluation

基　　金：2016年湖北省教育厅科学技术研究计划青年人才项目(B2016021);2015年湖北省自然科学基金面上项目(2015CFB316);湖北省卫生计生青年人才项目(WJ2015Q036);三峡大学人才科研启动基金(KJ2014B020)

摘　　要：1型糖尿病的发病率正在我国迅速增加,给治疗提出了新的要求。钠-葡萄糖共转运蛋白-2(Sodium Glucose Co-Transporter 2 inhibitor,SGLT-2)抑制剂是治疗2型糖尿病的新型口服降糖药。但是近几年来发现,它和胰岛素可以显著的降低1型成人糖尿病模型和患者的血糖,减少血糖波动和胰岛素用量,且不增加低血糖风险,这给广大的1型糖尿病带来了希望;但同时,其不良反应也不容忽视(酮症、泌尿生殖系感染),在青少年患者中疗效还有待进一步确认。本文讲总结各种SGLT-2抑制剂在治疗1型糖尿病的证据,为供临床医师参考。The booming prospect and demand were upsurging for treating type 1 diabetes whose incident in China was soaring in the past decades. SGLT-2i (Sodium Glucose Co-Transporter 2 inhibitor) was novel oral anti-hyperglycemic drug for type 2 diabetes, but in recent years, SGLT-2i and insulin combination therapy could significantly lower blood glucose in type 1 diabetes, decrease blood glucose fluctuation and insulin dosage and do not increase the risk of hypoglycemia, which brought promising prospect for type 1 diabetes;Meanwhile, the side effect would not be overlooked (such as ketosis and genitourinary infection). The effect on adolescent patients remain further validated. This review summarizes several evidence of medication on type 1 diabetes by SGLT-2i derivatives, which could provide the powerful suggestions for clinicians.

关 键 词：钠-葡萄糖共转运蛋白-2 抑制剂 1 型糖尿病 联合治疗 

分 类 号：R587.1[医药卫生—内分泌]